Author： Derosa Giuseppe Maffioli Pamela
Publisher： Informa Healthcare
ISSN： 1477-9072
Source： Expert Review of Cardiovascular Therapy, Vol.11, Iss.6, 2013-06, pp. : 719-728
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Diabetes is associated with left ventricular hypertrophy (LVH). This article reviews the assessment and management of LVH in Type 2 diabetic patients and the available evidence on blood-pressure management in these patients in order to reduce LVH. The best treatment of LVH starts with early identification and rapid implementation of adequate treatment, especially in populations at higher risk. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors should be the first-line therapy, because they are proven to be the most effective in reducing LVH in Type 2 diabetic patients. In patients where angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors are contraindicated or not tolerated, calcium-channel blockers should be the second option.
Related content
By Matsuno Yasunari Minatoguchi Shinya Fujiwara Hisayoshi
Blood Pressure, Vol. 20, Iss. 1, 2011-04 ,pp. :
Access to resources
Recommend
By Darmellah A. Baetz D. Prunier F. Tamareille S. Rücker-Martin C. Feuvray D.
Diabetologia, Vol. 50, Iss. 6, 2007-06 ,pp. :